# The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris

Study · id `cardio:ct-nct02870764` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02870764](<https://clinicaltrials.gov/study/NCT02870764>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02870764

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.

## Technical summary

Registry record NCT02870764. Randomized; triple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT02870764, source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)
- Start date: 2016-09 (registry gives no type) (ClinicalTrials.gov record NCT02870764, source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)
- Primary completion: 2017-05 (anticipated) (ClinicalTrials.gov record NCT02870764, source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)
- Completion: 2017-08 (anticipated) (ClinicalTrials.gov record NCT02870764, source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02870764, source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02870764-2016-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris
- Acronym: DOLPHIN
- Condition: Angina, Stable
- Condition: Inflammation
- Intervention (Drug): Dan-shen extract
- Intervention (Drug): Placebo
- Intervention (Other): Standard medical care
- Lead sponsor: Taizhou Fourth People's Hospital
- Lead sponsor class: OTHER
- Collaborator: Shanghai 10th People's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry lists this organization as a collaborator: Shanghai 10th People's Hospital (`cardio:org-shanghai-10th-people-s-hospital`)

## Provenance

Content hash: ff796f479e8719e42ae8f42ac9a2a86d531f31d13f90a06d459546067eaf5e05
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
